Company Profile
Cogent Biosciences Stock Price, News & Analysis
Company overview
Business overview
Cogent Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cogent Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Cogent Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Cogent Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
COGT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Cogent Biosciences's catalysts are bezuclastinib and the KIT-driven GIST / mastocytosis programs, where the next update can quickly reframe the story. The company still needs the next step to show the oncology platform can keep building.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
Source: Cogent Biosciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.